ArticleAllergy2020

Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation.

Audrey Le Floc'h et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.